Recent Advances in Treating Diffuse Large B-Cell Lymphoma

1. DLBCL is heterogeneous with subtypes benefitting from specific therapies. 2. Primary therapy includes prephase therapy and the addition of rituximab to CHOP. 3. Treatment for patients who fail to respond to primary therapy includes autologous stem cell transplant, CAR T-cell therapy, and bispecific antibodies. 4. Emerging use of ctDNA to assess treatment response. 5. The ViPOR regimen shows promise for specific DLBCL subtypes.